Definium Therapeutics, Inc. (DFTX) Q3 2025 10-Q Quarterly Report
Filed: Nov 6, 2025Period ending Sep 30, 2025
Health Care
Medicinal Chemicals & Botanical ProductsSEC EDGAR Definium Therapeutics, Inc. (DFTX) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Definium Therapeutics, Inc. Q3 2025 10-Q Analysis
Risk Factors
- • New risk: Increased R&D expense due to accelerated Phase 3 trials for MM120 in GAD and MDD, driven by expanded participant enrollment and adaptive trial design
- • Updated material risk: Volatility in fair value of 2022 USD Financing Warrants caused $22.5M loss in Q3 2025, reflecting increased share price since June 2025
- • Regulatory risk: Ongoing FDA review with potential changes to Phase 3 trial designs for MM120 could delay approvals or increase costs
- • Operational risk: Need to scale up personnel and commercial preparedness leading to 93% increase in G&A expenses to $14.7M in Q3 2025 impacting near-term cash burn
- • Financial risk: Raised net proceeds of $242.8M in Oct 2025 equity offering, cash balance $209.1M as of Sept 30, 2025, expected to fund operations into 2028 under current plan
Definium Therapeutics, Inc. Q3 2025 Quarterly FinancialsXBRL
Net Income
-$67M
▼ -391.6% YoY▼ -57.4% QoQ
ROE
-51.5%
Total Assets
$237M
EPS (Diluted)
$-0.75
▼ -581.8% YoY▼ -63.0% QoQ
Operating Cash Flow
-$30M
▼ -72.0% YoY▲ +0.1% QoQ
Source: XBRL data from Definium Therapeutics, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Definium Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.